Cagrilintide

What is Cagrilintide?

Cagrilintide is an investigational medication being studied for weight loss and blood sugar control in people with obesity or type 2 diabetes. It is a synthetic version of a natural hormone called amylin that your body normally makes in the pancreas. This medication is given as a once-weekly injection under the skin, similar to other diabetes and weight loss medications you may have heard about. It is currently being tested in clinical trials and is not yet approved by the FDA for general use.

How Does It Work?

Cagrilintide works by mimicking amylin, a hormone that helps control your appetite and how quickly food moves through your stomach. When you take cagrilintide, it helps you feel fuller for longer after eating, reduces your appetite, and slows down how fast your stomach empties after meals. These effects help you eat less and lose weight over time. For people with diabetes, it also helps control blood sugar levels by slowing down how quickly sugar from food enters your bloodstream. The medication is designed to last a full week in your body, which is why you only need to inject it once weekly.

How to Take Cagrilintide

If prescribed cagrilintide, you will inject it under the skin of your stomach, thigh, or upper arm once a week. You can take it on any day of the week and at any time, with or without food, but try to use the same day each week. Your doctor will start you on a low dose and gradually increase it over several weeks or months. This slow increase helps your body adjust and reduces side effects like nausea. It's important to follow your doctor's instructions exactly and not to skip doses or increase the dose on your own. If you miss a dose and remember within 5 days, take it as soon as possible. If it's been more than 5 days, skip that dose and take your next dose on the regular schedule.

Common Side Effects and What to Watch For

The most common side effects of cagrilintide are stomach-related and include nausea, vomiting, diarrhea, constipation, and stomach pain. These side effects are usually worst when you first start the medication or when your dose is increased, and they often get better over time. To help manage nausea, eat smaller meals, avoid fatty or spicy foods, and stay well-hydrated. Other common side effects include headache, tiredness, and mild reactions at the injection site. Contact your doctor right away if you experience severe stomach pain that doesn't go away (which could be a sign of pancreatitis), severe vomiting that leads to dehydration, symptoms of low blood sugar (if you're also taking insulin or certain diabetes pills), or signs of gallbladder problems like pain in the upper right side of your stomach, fever, or yellowing of your skin or eyes. If you're taking other medications, especially birth control pills or antibiotics, talk to your doctor about the best timing for taking them, as cagrilintide can affect how your body absorbs other medicines.

Cagrilintide represents a novel therapeutic approach in the management of obesity and type 2 diabetes mellitus through its mechanism as a long-acting amylin analogue. Developed by Novo Nordisk, this investigational peptide compound builds upon the physiological understanding of amylin's role in metabolic regulation and appetite control. Native amylin, discovered in the 1980s, was recognized as an important hormone in glucose homeostasis and satiety signaling, but its extremely short half-life limited its therapeutic utility. Cagrilintide was engineered with structural modifications to dramatically extend its duration of action, enabling once-weekly subcutaneous administration.

The development of cagrilintide has progressed through extensive preclinical and clinical evaluation. Phase 1 studies established the safety, tolerability, and pharmacokinetic profile of the compound across a range of doses, with single ascending dose studies evaluating doses from 10 mcg to 1100 mcg, and multiple ascending dose studies examining doses up to 6000 mcg (6 mg). These early studies demonstrated dose-dependent weight loss, with the highest doses in the multiple ascending dose cohorts achieving up to 12.6% weight loss at 12 weeks. The compound has since advanced to Phase 2 and Phase 3 clinical trials evaluating its efficacy and safety in various populations.

Cagrilintide is being investigated both as monotherapy and in combination with other anti-obesity and anti-diabetic medications, most notably with semaglutide, a GLP-1 receptor agonist. The rationale for combination therapy stems from the complementary mechanisms of action: while GLP-1 agonists primarily work through GLP-1 receptor activation to enhance insulin secretion, suppress glucagon, and slow gastric emptying, cagrilintide adds amylin-mediated effects on satiety and food intake regulation. Clinical trials have explored various combination ratios and dosing regimens to optimize the therapeutic benefit while managing tolerability.

The primary therapeutic applications under investigation include weight management in adults with obesity or overweight (with or without comorbidities), treatment of type 2 diabetes mellitus with concurrent weight reduction, and potentially cardiovascular risk reduction in patients with established cardiovascular disease. Clinical trial programs have enrolled diverse patient populations, including those with painful diabetic peripheral neuropathy, children and adolescents with type 2 diabetes, and patients across various BMI categories and metabolic profiles.

If approved, cagrilintide would represent an important addition to the therapeutic armamentarium for obesity and metabolic disease, offering a mechanistically distinct approach that could be used alone or in combination with existing therapies. The once-weekly dosing schedule would provide a convenient administration option that may improve adherence compared to daily or multiple-daily injection regimens. The ongoing clinical trial program will determine the ultimate role of cagrilintide in clinical practice and its position relative to other available weight management and diabetes therapies.

Cagrilintide is a synthetic long-acting analogue of human amylin (islet amyloid polypeptide), a 37-amino acid neuroendocrine hormone that is co-secreted with insulin from pancreatic beta cells in response to nutrient intake. The compound has been structurally modified to extend its half-life and improve its pharmacokinetic profile compared to native amylin, which has a very short half-life of approximately 13 minutes.

Cagrilintide exerts its therapeutic effects primarily through activation of amylin receptors, which are G-protein coupled receptors formed by the calcitonin receptor (CTR) in complex with receptor activity-modifying proteins (RAMPs), particularly RAMP1 and RAMP3. These receptors are highly expressed in the area postrema and nucleus tractus solitarius of the brainstem, regions critical for the regulation of satiety and food intake. Upon binding to these receptors, cagrilintide activates intracellular signaling cascades involving cyclic AMP (cAMP) production and downstream effector pathways.

The primary physiological effects of cagrilintide include reduction of food intake through enhanced satiety signaling, slowing of gastric emptying which prolongs the sensation of fullness after meals, and modulation of postprandial glucagon secretion. These mechanisms collectively contribute to reduced caloric intake and improved glycemic control. The slowing of gastric emptying helps attenuate postprandial glucose excursions by delaying the absorption of nutrients from the gastrointestinal tract.

Additionally, amylin receptor activation in the central nervous system influences energy homeostasis through effects on hypothalamic circuits that regulate appetite and energy expenditure. The long-acting formulation of cagrilintide allows for once-weekly subcutaneous administration, providing sustained receptor activation and consistent therapeutic effects throughout the dosing interval, which represents a significant advantage over short-acting amylin analogues like pramlintide that require multiple daily injections.

General Dosing Principles

Cagrilintide is administered as a subcutaneous injection once weekly. The dosing strategy employs gradual dose escalation to improve gastrointestinal tolerability and minimize adverse events, particularly nausea and vomiting. The rate of dose escalation and target maintenance dose vary depending on the indication, patient population, and whether cagrilintide is used as monotherapy or in combination with other agents.

Obesity and Weight Management (Adults)

Monotherapy Dosing

Alternative escalation schedules have been evaluated in clinical trials, with some protocols using 2-week intervals between dose increases (weeks 1-2: 0.25 mg; weeks 3-4: 0.5 mg) and target maintenance doses ranging from 2.4 mg to 4.5 mg weekly depending on the specific protocol.

Combination Therapy with GLP-1 Receptor Agonists

When used in combination with semaglutide or other GLP-1 receptor agonists, dose escalation periods of 8-16 weeks have been employed to reach target maintenance doses. The specific escalation schedule should balance efficacy with tolerability, with slower titration generally associated with better gastrointestinal tolerability.

Type 2 Diabetes Mellitus (Adults)

Standard Titration Schedule

Clinical trials have evaluated 8-week and 16-week dose escalation periods to reach target maintenance doses. The longer 16-week escalation may be preferred in patients with significant gastrointestinal sensitivity or those receiving multiple glucose-lowering medications.

Type 2 Diabetes in Children and Adolescents

Pediatric dosing should be individualized based on tolerability and response, with careful monitoring for adverse effects.

Cardiovascular Disease Population

In patients with established cardiovascular disease (with or without type 2 diabetes), dose escalation over 16 weeks has been evaluated, starting at 0.25-0.5 mg weekly and escalating to target maintenance doses based on tolerability.

Administration Instructions

• Administer subcutaneously in the abdomen, thigh, or upper arm

• Rotate injection sites with each dose to reduce injection site reactions

• Can be administered at any time of day, with or without meals

• If a dose is missed, administer as soon as possible if within 5 days of the scheduled dose; if more than 5 days have passed, skip the missed dose and resume with the next scheduled dose

• Do not administer two doses within 3 days of each other

Dose Adjustments

Renal Impairment

No specific dose adjustments have been established in clinical trials for patients with renal impairment. Use with caution and monitor closely, as peptide clearance may be affected.

Hepatic Impairment

No specific dose adjustments have been established for hepatic impairment. Given the peptide nature of cagrilintide and its non-hepatic metabolism, significant dose adjustment may not be necessary, but clinical data are limited.

Geriatric Patients

No specific dose adjustments based solely on age have been established. Dose selection should be individualized based on tolerability and response, with consideration of age-related changes in renal function and increased likelihood of concomitant medications.

Discontinuation

If treatment is discontinued for more than 4 weeks, reinitiation should follow the initial dose escalation schedule to minimize gastrointestinal adverse events.

The clinical development program for cagrilintide encompasses a comprehensive series of trials evaluating its efficacy and safety across multiple indications and patient populations. Phase 1 studies established the fundamental safety and pharmacokinetic profile of the compound. In single ascending dose studies, doses ranging from 10 mcg to 1100 mcg were evaluated, establishing dose-proportional pharmacokinetics and acceptable tolerability. Multiple ascending dose studies examined weekly doses up to 6000 mcg (6 mg) over 12 weeks, with the highest dose cohorts demonstrating clinically significant weight loss of up to 12.6% from baseline, providing early proof-of-concept for the compound's weight-reducing effects.

Phase 2 trials have explored various dosing regimens and patient populations. In studies of adults with obesity or overweight, cagrilintide monotherapy has been evaluated with dose escalation periods ranging from 8 to 16 weeks, followed by maintenance periods extending up to 52 weeks. Target maintenance doses have varied across studies, with some protocols evaluating doses up to 4.5 mg weekly. These trials have consistently demonstrated dose-dependent weight loss, with higher doses generally producing greater reductions in body weight. Gastrointestinal adverse events, particularly nausea and vomiting, have been the most common treatment-related side effects, with incidence and severity influenced by the rate of dose escalation.

A particularly important aspect of the clinical program has been the evaluation of cagrilintide in combination with semaglutide, a GLP-1 receptor agonist. The rationale for this combination is based on complementary mechanisms of action, with amylin and GLP-1 pathways both contributing to appetite regulation and glucose homeostasis through distinct receptor systems. Clinical trials have evaluated various dose combinations, with semaglutide doses up to 2.4 mg weekly combined with cagrilintide doses ranging from 0.5 mg to higher levels. Combination therapy has generally produced greater weight loss than either agent alone, with some studies reporting mean weight reductions exceeding 15-20% from baseline in the combination arms.

Clinical trials in patients with type 2 diabetes have evaluated cagrilintide both as monotherapy and as add-on therapy to existing glucose-lowering medications. These studies have employed dose escalation periods of 8-16 weeks to reach target maintenance doses, with treatment periods extending 32-40 weeks. In addition to weight loss, these trials have assessed glycemic endpoints including HbA1c reduction, fasting plasma glucose, and postprandial glucose excursions. Results have shown clinically meaningful improvements in glycemic control alongside significant weight reduction, a particularly valuable combination for patients with type 2 diabetes who often struggle with weight management.

Special population studies have expanded the clinical evidence base. Trials in children and adolescents with type 2 diabetes have evaluated doses up to 1.0 mg weekly with gradual titration schedules starting at 0.25 mg. Studies in patients with cardiovascular disease, with or without type 2 diabetes, are investigating potential cardiovascular benefits of cagrilintide therapy. Additional trials are examining the compound's effects in patients with painful diabetic peripheral neuropathy, exploring whether weight loss and improved metabolic control might provide symptomatic benefits. Phase 3 trials are ongoing to provide definitive evidence of efficacy and safety for regulatory submissions, with large-scale studies enrolling thousands of participants across diverse geographic regions and patient populations.

Contraindications

While specific absolute contraindications have not been fully detailed in the available clinical trial data, the following would be expected contraindications based on the mechanism of action and class effects:

• Known hypersensitivity to cagrilintide or any component of the formulation

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Diabetic ketoacidosis

• Severe gastroparesis or conditions where delayed gastric emptying would be contraindicated

Warnings and Precautions

Gastrointestinal Adverse Reactions

The most common adverse reactions associated with cagrilintide are gastrointestinal in nature, including nausea, vomiting, diarrhea, constipation, and abdominal pain. These effects are mechanism-based, resulting from slowed gastric emptying and central effects on satiety signaling. Nausea is typically most pronounced during dose escalation and tends to diminish over time with continued treatment. Gradual dose titration is essential to minimize these effects. Severe or persistent vomiting may lead to dehydration and electrolyte abnormalities, requiring temporary dose reduction or treatment discontinuation.

Hypoglycemia

When used as monotherapy, cagrilintide is not expected to cause significant hypoglycemia as it does not directly stimulate insulin secretion. However, when used in combination with insulin or insulin secretagogues (sulfonylureas, meglitinides), the risk of hypoglycemia is increased. Dose reduction of concomitant insulin or insulin secretagogues may be necessary when initiating cagrilintide. Patients should be educated on hypoglycemia recognition and management.

Thyroid C-Cell Tumors

As with other peptide therapies in development for obesity and diabetes, there is theoretical concern regarding thyroid C-cell tumors based on preclinical rodent studies. While the clinical relevance to humans remains uncertain, patients should be counseled about symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness) and monitored appropriately. Routine calcitonin monitoring is not recommended but may be considered in high-risk patients.

Acute Pancreatitis

Peptide-based therapies for obesity and diabetes have been associated with acute pancreatitis in post-marketing surveillance and clinical trials. Patients should be informed about symptoms of acute pancreatitis (severe persistent abdominal pain, sometimes radiating to the back, with or without vomiting). If pancreatitis is suspected, cagrilintide should be discontinued promptly and not restarted unless an alternative etiology is confirmed.

Gallbladder Disease

Rapid weight loss, as may occur with cagrilintide therapy, is associated with increased risk of cholelithiasis and cholecystitis. Patients should be educated about symptoms of gallbladder disease and monitored clinically. Ultrasound evaluation may be warranted if symptoms develop.

Renal Impairment

Gastrointestinal adverse events leading to dehydration may worsen renal function, particularly in patients with pre-existing renal impairment. Adequate hydration should be maintained, and renal function should be monitored in at-risk patients.

Drug Interactions

Due to delayed gastric emptying, cagrilintide may affect the absorption of concomitantly administered oral medications. This is particularly relevant for medications requiring rapid absorption or those with narrow therapeutic indices, including oral contraceptives, antibiotics, and anticoagulants. Appropriate timing of medication administration should be considered.

Common Adverse Effects

Based on clinical trial data, the most frequently reported adverse effects include:

• Very Common (>10%): Nausea, vomiting, diarrhea

• Common (1-10%): Constipation, abdominal pain, dyspepsia, decreased appetite, headache, fatigue, dizziness, injection site reactions

• Gastrointestinal effects: Typically most prominent during dose escalation, often transient, and generally mild to moderate in severity

Serious Adverse Effects

• Severe hypoglycemia (when combined with insulin or insulin secretagogues)

• Acute pancreatitis

• Acute gallbladder disease

• Severe dehydration due to persistent vomiting

• Acute kidney injury secondary to volume depletion

• Severe allergic reactions (rare)

Special Populations

Pregnancy

There are no adequate data on cagrilintide use in pregnant women. Weight loss during pregnancy is not recommended regardless of pre-pregnancy weight. Cagrilintide should be discontinued if pregnancy occurs or is planned. Animal reproductive studies would need to be reviewed for specific developmental toxicity data.

Lactation

It is unknown whether cagrilintide is excreted in human breast milk. The effects on the breastfed infant and on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for cagrilintide and any potential adverse effects on the breastfed infant.

Pediatric Use

Clinical trials have evaluated cagrilintide in children and adolescents with type 2 diabetes at doses up to 1.0 mg weekly. Safety and efficacy in pediatric populations for obesity management have not been established. Growth and development should be monitored in pediatric patients receiving treatment.

Geriatric Use

Clinical studies have included patients 65 years and older. While no overall differences in safety or efficacy have been identified, greater sensitivity in some older individuals cannot be ruled out. Dose selection should be cautious, considering age-related decreases in renal function and increased likelihood of concomitant disease and drug therapy.

Monitoring Parameters

• Body weight (regularly throughout treatment)

• Blood glucose and HbA1c (in patients with diabetes)

• Renal function (baseline and periodically, especially in patients at risk)

• Signs and symptoms of pancreatitis

• Signs and symptoms of gallbladder disease

• Hydration status, particularly during dose escalation

• Heart rate (baseline and periodically)

• Injection site reactions

• Symptoms of hypoglycemia (when used with insulin or insulin secretagogues)

Pharmacokinetics

Cagrilintide exhibits pharmacokinetic properties consistent with a long-acting peptide designed for once-weekly subcutaneous administration. Following subcutaneous injection, the compound demonstrates sustained absorption with a prolonged time to maximum plasma concentration (Tmax), typically occurring several days after administration. The extended absorption profile is achieved through structural modifications that increase molecular size and alter the physicochemical properties of the peptide, promoting gradual release from the subcutaneous depot and reducing renal clearance.

The elimination half-life of cagrilintide is approximately 5-7 days, which supports the once-weekly dosing regimen and provides relatively stable plasma concentrations throughout the dosing interval. This represents a dramatic improvement over native amylin, which has a half-life of only 13 minutes. The volume of distribution is relatively limited, consistent with a large peptide molecule that does not extensively distribute into tissues beyond the vascular and interstitial compartments. Steady-state concentrations are typically achieved after 3-4 weeks of regular weekly dosing.

Metabolism of cagrilintide occurs primarily through proteolytic degradation, as is typical for peptide therapeutics. The compound is broken down into smaller peptide fragments and individual amino acids through the action of various peptidases and proteases present in plasma and tissues. Unlike small molecule drugs, cagrilintide does not undergo hepatic cytochrome P450-mediated metabolism, which reduces the potential for drug-drug interactions related to metabolic enzyme inhibition or induction. Elimination occurs through multiple pathways including renal filtration of degradation products and cellular uptake with subsequent lysosomal degradation.

Pharmacodynamics

The pharmacodynamic effects of cagrilintide are dose-dependent and correlate with plasma exposure levels. Key pharmacodynamic endpoints include reduction in food intake, decreased body weight, slowing of gastric emptying (as measured by paracetamol absorption tests or gastric scintigraphy), and improvements in glycemic parameters in patients with type 2 diabetes. The onset of weight loss typically begins within the first few weeks of treatment and continues progressively with ongoing therapy, with maximal effects generally observed after several months of treatment at maintenance doses.

Gastric emptying is significantly delayed by cagrilintide, with effects persisting throughout the dosing interval. This contributes to both the weight loss effects (through enhanced and prolonged satiety) and the glucose-lowering effects (through delayed carbohydrate absorption). In patients with type 2 diabetes, cagrilintide produces reductions in fasting plasma glucose, postprandial glucose excursions, and HbA1c levels. The glucose-lowering effects are achieved without directly stimulating insulin secretion, distinguishing cagrilintide from insulin secretagogues and reducing the risk of hypoglycemia when used as monotherapy.

Drug Interactions

Due to its mechanism of action in slowing gastric emptying, cagrilintide has the potential to affect the absorption of concomitantly administered oral medications. This is particularly relevant for medications with narrow therapeutic indices or those requiring rapid absorption for optimal efficacy. Patients taking oral contraceptives, antibiotics requiring specific timing, or other time-sensitive medications should be counseled on appropriate timing of administration relative to cagrilintide dosing. However, because cagrilintide is administered weekly rather than daily, and its effects on gastric emptying are relatively consistent throughout the dosing interval, the clinical significance of these interactions may differ from that seen with shorter-acting agents.

Cagrilintide does not interact with cytochrome P450 enzymes and is not expected to cause pharmacokinetic drug interactions through metabolic pathways. When used in combination with other glucose-lowering medications, particularly insulin or insulin secretagogues, there may be an increased risk of hypoglycemia, and dose adjustments of these concomitant medications may be necessary. The combination of cagrilintide with GLP-1 receptor agonists has been extensively studied in clinical trials, and while both agents slow gastric emptying, the combination appears to be generally well-tolerated with manageable gastrointestinal side effects when appropriate dose titration schedules are followed.